Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) [Trend Analysis] retains strong position in active trade, as shares scoring 3.49% to $70.96 in a active trade session, while looking at the shares volume, about 83388 shares have changed hands in this session. Alnylam Pharmaceuticals, Inc. (ALNY) revealed that upon recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC) to suspend dosing, the Firm has decided to discontinue development of revusiran, an examinational RNA interference (RNAi) therapeutic that was being developed for the treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM).
This decision was made yesterday evening and has been communicated to investigators, study sites, and regulatory authorities. Following recent reports in the Phase 2 OLE study of new onset or worsening peripheral neuropathy, the ENDEAVOUR DMC assembled yesterday at the Firm’s request to review these reports and ENDEAVOUR data on an unblinded basis.
The DMC did not find conclusive evidence for a drug-related neuropathy signal in the ENDEAVOUR trial, but informed the Firm that the benefit-risk profile for revusiran no longer supported continued dosing. The firm has institutional ownership of 88.70%, while insider ownership included 0.20%. ALNY attains analyst recommendation of 2.00 with week’s performance of -12.19%. Investors looking additional ahead will note that the Price to next year’s EPS is -8.40%.
Mylan N.V. (NASDAQ:MYL) [Trend Analysis] knocking active thrust in leading trading session, shares a gain of 0.76% to 38.26 with about 1.25 Million shares have changed hands in this session. The federal government reported that Mylan NV has overcharged the federal-state Medicaid program by millions of dollars over five years for its emergency auto-injector product called the EpiPen. In a letter Wednesday, Acting Administrator Andy Slavitt of the federal Centers for Medicare and Medicaid Services (CMS), stated Mylan wrongly classified the emergency epinephrine product as a generic, when it should have been classified as a brand-name product The stock is going forward its fifty-two week low with 2.27% and lagging behind from its 52-week high price with -31.08%.
Same, the positive performance for the quarter recorded as -12.79% and for the year was -13.51%, while the YTD performance remained at -29.78%. MYL has Average True Range for 14 days of 1.18.